MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Abbott buys into electrophysiology with $250m Topera acquisition

Abbott buys into electrophysiology with $250m Topera acquisition

By

Abbott buys into electrophysiology with $250m Topera acquisition

Abbott (NYSE:ABT) said today that it’s buying into the electrophysiology business with a pair of acquisitions, a $250-million-plus deal for Topera Medical and another transaction for Advanced Cardiac Therapeutics and its ablation catheter.

The deal for Menlo Park, Calif.-based Topera and its cardiac arrhythmia mapping technology includes an unspecified amount pegged to "performance milestones," Abbott said.

Topera won 510(k) clearance from the FDA in January for the latest incarnation of its 3D mapping system, including the RhythmView workstation and FIRMap diagnostic catheter. The imaging system uses electrical signals, captured by a multipolar electrophysiology catheter, and creates a 3D image that can more accurately map cardiac arrhythmias.

Abbott said it also inked a deal for the right to acquire Santa Clara, Calif.-based Advanced Cardiac Therapeutics "upon completion of key milestones" for an unspecified amount. ACT is developing the TempaSure ablation catheter designed to improve the safety and effectiveness of ablation procedures.

"There is significant room to use advanced rotor identification technologies to improve the success rate and reduce the need for multiple ablation procedures, and thus improve the health of people with atrial fibrillation," Abbott medical devices executive vice president John Capek said in prepared remarks. "The Topera acquisition and our agreement with ACT provide a foundational entry into the large, high-growth electrophysiology market, with differentiated technologies that can transform the way physicians treat people with complex heart rhythm disorders."

"Topera’s mapping technology has the potential to change the paradigm for how physicians approach treating people with atrial fibrillation," added Dr. John Miller of Indiana University Health. "The ability to more accurately target the areas of the heart perpetuating atrial fibrillation is a significant advancement in the field of electrophysiology, which may allow us to treat more people with atrial fibrillation and lead to better health results."

Abbott said it tapped VytronUS president & CEO Michael Pederson to lead its new EP business. The deal for Topera is expected to close during the 4th quarter, according to a press release.

In case you missed it

RSS From Medical Design & Outsourcing

  • Tegra Medical announces new director of sales and marketing in Europe
    Tegra Medical announced that it appointed Darren Vine as its director of sales and marketing in Europe. Franklin, Mass.-based Tegra said in a news release that Vine will report to CEO and head of SFS division medical Walter Kobler, with responsibilities including the building of the company’s presence through expansion into new markets around the… […]
  • 5 challenges Boston Scientific overcame to make single-use scopes work
    FDA wanted single-use scopes to reduce potentially deadly superbug infections. Here’s how Boston Scientific made it happen. Boston Scientific’s Exalt Model D Single-Use Duodenoscope received FDA clearance in December 2019. It was the first device of its kind to hit the medical market. Just five months earlier, the FDA urged device manufacturers to move away from re-usable duodenoscopes with… […]
  • Veranex acquires Experien Group
    Veranex announced today that it acquired Experien Group, a provider of regulatory, quality and clinical consulting services for medtech companies. Raleigh, N.C.-based Veranex, which was created as a combination of companies after Summit Partners acquired Ximedica, Quartesian and Boston Healthcare Associates in June, offers integrated product development strategies and services to medtech companies. According to… […]
  • How Olympus is using AI to find patients for its COPD device
    Olympus recently announced its SeleCT Connect program, which uses diagnostic imaging AI to automatically screen which people might benefit from its Spiration valve system. Spiration is an FDA-designated breakthrough device for treating chronic obstructive pulmonary disease (COPD) patients. SeleCT Connect — offered as part of Olympus’ SeleCT quantitative computer tomography (QCT) analysis service — is… […]
  • Catheter & Medical Design and VitalDyne Medical rebrand as VitalPath
    Catheter & Medical Design and VitalDyne Medical — makers of complex medical catheter systems — have rebranded under the name VitalPath. The move comes about five months after CMD’s March 2021 acquisition of VitalDyne. The Roseville, Minn.–based company also has a new website at vitalpath.com. VitalPath will exhibit at booth  No. 1714 at MD&M West,… […]
  • Dymax touts newest formulations for medtech wearables
    Dymax is using MD&M West in Anaheim, Calif. next week to tout its newest formulations for assembling medical device wearables. The Dymax materials are free from IBOA and TPO, are compatible with common and difficult substrates, and have passed ISO 10993-10 for sensitization and irritation, according to the Torrington, Conn.–based company. For manufacturers involved with… […]
  • What is a proportional isolation valve?
    A “proportional” isolation valve can bring the next level of control and design for engineers, especially in life science industries. Doug Paynter, Clippard When we talk about proportional valves, whether they are pneumatic or hydraulic, we typically refer to valves that vary their flow path when you apply an increasing or decreasing amount of power/current… […]
  • CoorsTek scores EU legal win in pink components trademark dispute
    The EU Trademark Court of Appeals in Paris recently upheld a Paris EU Trademark High Court decision that sided with CoorsTek against CeramTec in a trademark dispute over “pink” ceramic hip components. The Paris Court of Appeals in its June 2021 ruling upheld the cancelations of the three EU trademarks and the dismissal of CeramTec’s… […]
  • Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
    Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West remembers… […]
  • Versapor® RC Membranes: The next generation of venting materials
    As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications… […]
  • Tips to help bring your medical device from mind to market
    By Bret Ludwig, Ph.D. Senior Product Development Specialist, 3M Medical Materials & Technologies Great medical devices start with an idea—a spark. And from there, it might move to the back of a napkin or a notepad. But as development continues, the process can get trickier and more complex. In fact, turning an idea into a… […]

Leave a Reply